Abstract

To observe the therapeutic effect of nitroglycerin in conjunction with low molecular weight heparin sodium in managing angina pectoris in individuals with coronary heart disease. Between June 2022 and June 2023, our hospital received 414 patients with angina due to coronary heart disease who were enrolled in the study. They were randomly assigned to either a control group (210 cases) or an observation group (204 cases). Aspirin and calcium channel blockers were prescribed based on individual patient evaluations to ensure optimal therapeutic outcomes. Alongside the standard treatment, the control group was subjected to nitroglycerin intravenous infusion, while the observation group received a combination therapy involving both nitroglycerin intravenous infusion and low molecular weight heparin sodium treatment subsequent to the initial treatment. The assessment of therapeutic efficacy was conducted following a 2 w course of treatment. The effectiveness of treatment in the observation group was notably higher, with a total effective rate of 90.20 %, as compared to the control groups’ rate of 78.10 %, thus highlighting a statistically significant difference (p<0.05). In the observation group, there was a notable reduction in the duration and frequency of angina attacks, surpassing the control group with statistically significant differences (p<0.05). After the administration of treatment, both stroke volume and the 6 min walking distance exhibited significant increases. Of particular significance, these improvements were significantly more apparent in the observation group in comparison to the control group (p<0.05). The utilization of nitroglycerin in conjunction with low molecular weight heparin sodium yields significant, short-term therapeutic benefits for individuals suffering from angina pectoris associated with coronary heart disease. This combined treatment approach leads to a notable reduction in the frequency and duration of angina attacks while enhancing cardiac function.